HOME > COLUMN
COLUMN
-
The Patient North Star: How Gilead Japan Redefined Innovation
April 8, 2026
-
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
March 27, 2026
-
The Strategic MSL: Beyond Data Delivery, It’s About Impact
February 19, 2026
-
AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential
January 27, 2026
-
AI: Your New HR BFF (Not Your Replacement!)
December 24, 2025
-
AI in HR: Navigating the Ethical Minefield
November 28, 2025
-
The Unseen Edge & the Shadow of Bias: Awareness as the Cornerstone of Leadership Success
October 31, 2025
-
The Keen Eye: Awareness as a Leadership Cornerstone
September 29, 2025
-
A “50-Billion-Yen Plus” Newcomer
September 4, 2025
-
AI in Japanese Pharma: Now, Not Later!
August 29, 2025
-
Beyond the Bench: Why Biopharma Needs Strategic Thinkers
July 28, 2025
-
AI Is Redefining Healthcare: Insights from Prospection Japan’s Conference
June 27, 2025
-
Bridging the Talent Gap: Communication Challenges in Japan’s Pharma & Multinationals
May 30, 2025
-
The Evolution of HR: From BP to Agile
April 28, 2025
-
Build a Strong Employer Brand - What Can You Do If Your Company Stinks?
March 19, 2025
-
4 Things Your Firm Can Do to Attract and Retain Top Talent in Japan’s Pharmaceutical and Medical Device Industry
February 14, 2025
-
A Conversation with Bill Schuster: Navigating the Complexities of Healthcare Leadership
January 24, 2025
-
A Conversation with James Feliciano: Navigating the Complexities of the Japanese Pharmaceutical Industry
December 23, 2024
-
How to Be a Country Manager
November 29, 2024
-
Elevating Leadership: Insights from Japan’s Healthcare Sector
October 23, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
